Visit Opsens at C3 2019

Learn more about the benefits of OptoWire® as a pressure guidewire to diagnose and treat with confidence at the C3 2019 Conference by attending Opsens’ complimentary lunch  and educational symposium.  The OptoWire features a large nitinol core with excellent torque response and deliverability. With the OptoWire you can diagnose and treat your patients with confidence. Opsens second […]

Read More…

Visit Opsens at EuroPCR 2019

Learn more about the benefits of OptoWire® as a pressure guidewire to diagnose and treat with confidence at EuroPCR 2019 by attending Opsens’ complimentary Case-In-Point session or visit Opsens at the exhibition: Booth #64, level 2. The OptoWire features a large nitinol core with excellent torque response and deliverability. With the OptoWire you can diagnose and treat your patients with […]

Read More…

OPSENS SIGNS LANDMARK SUPPLIER AGREEMENT – EXPANDS OPTICAL SENSING TECHNOLOGY IMPACT WITHIN CARDIOLOGY SEGMENT

Quebec City, Quebec, April 30, 2019 – Opsens inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) is pleased to announce it has entered into a supply agreement as part of its long-term collaboration with Abiomed, Inc. (“Abiomed”) for the Impella CP® heart pump. Abiomed has awarded Opsens a five-year agreement to supply a critical component for […]

Read More…

Visit Opsens at SCAI 2019

Learn more about the benefits of OptoWire® as a pressure guidewire to diagnose and treat with confidence at SCAI 2019 (Society for Cardiovascular Angiography & Interventions) by attending Opsens’ complimentary lunch  and educational symposium.  Register Now! The OptoWire features a large nitinol core with excellent torque response and deliverability. With the OptoWire you can diagnose and treat […]

Read More…

OPSENS – Q2 2019 REVENUES REACH $7.9 M, A 46% INCREASE

Quebec City, Quebec, April 11, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the second quarter of 2019. Highlights Consolidated revenues totaled $7.9 M in the second quarter of 2019 compared with $5.4 M in the corresponding period in 2018, an increase of $2.5 M or 46%; Fractional […]

Read More…

Visit Opsens at St. Francis Optimizing PCI (OPCI) 2019

Learn more about the benefits of OptoWire® as a pressure guidewire to diagnose and treat with confidence at the St. Francis Optimizing PCI (OPCI): Intravascular Imaging & Coronary Physiology Conference by attending Opsens’ complimentary hands-on workshop.  Space is limited, reserve your seat now!  Hands-On Workshop “Right Technique, Right Device for Physiologic Assessments” Saturday, March 9, 2019 Program Times: […]

Read More…

OPSENS APPOINTS ALAN MILINAZZO AS EXECUTIVE CHAIRMAN OF THE BOARD OF DIRECTORS

Quebec City, Quebec, March 4, 2019 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) is pleased to announce the appointment of Mr. Alan Milinazzo as Executive Chairman of the Board of Directors. “We are delighted to see Alan, a renowned leader in the medical device industry, join us. Alan has had extensive success in building high-performance commercial […]

Read More…

OPSENS ANNOUNCES CREDIT AGREEMENT WITH CIBC INNOVATION BANKING

OPSENS ANNOUNCES CREDIT AGREEMENT WITH CIBC INNOVATION BANKING Quebec City, Quebec, February 27, 2019 – Opsens Inc. (“Opsens”) (TSX:OPS) (OTCQX:OPSSF) ) is pleased to announce that it has entered into an $8 M credit agreement (the “Agreement”) with CIBC Innovation Banking (CIBC). “The Agreement offered carries excellent conditions. We are proud of the confidence shown by the […]

Read More…

ATTEND THE OPSENS SPONSORED LUNCH SYMPOSIUM AT CRT 2019

Attend the Opsens sponsored complimentary lunch educational symposium, “Coronary Physiology 2019: Covering All Your (Physiologic) Bases” at the CRT (Cardiovascular Research Technologies) 2019 Conference in Washington, DC. The OptoWire features a large nitinol core with excellent torque response and deliverability. With the OptoWire you can diagnose and treat your patients with confidence. Opsens second generation fiber optic […]

Read More…

OPSENS – Q1 2019 REVENUES REACH A RECORD HIGH OF $9.1 M, A 43% INCREASE

Quebec City, Quebec, January 14, 2019 – Opsens Inc. (“Opsens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF) today reported its results for the first quarter of 2019. Highlights Consolidated revenues totaled $9.1 M in the first quarter of 2019 compared with $6.4 M in the corresponding period in 2018, an increase of $2.7 M or 43% and […]

Read More…

This website uses cookies to ensure you get the best experience on our website.